AVI BioPharma gets patent allowance for antibacterial technology

By Elaine Rigoli

Tampa, Fla., May 24 - AVI BioPharma, Inc. announced that it has received a Notice of Allowance for U.S. Patent No. 7,049,431 titled "Antisense Antibacterial Cell Division Composition and Method."

The patent describes the use of NeuGene antisense compounds to target bacterial cell division and cell cycle genes for the development of a new class of antibiotics.

This is the central patent covering AVI's antibiotic development program referred to as NeuBiotics.

"This antisense approach to the development of a new class of antibiotics has broad potential to treat infections caused by emerging strains of antibiotic-resistant gram-positive bacteria," said Patrick L. Iversen, senior vice president of research and development at AVI, in a news release.

"We believe we can continue to explore the use of NeuGene antibiotics to include a variety of gene targets, newly emerging infectious disease and enhance the potency and efficacy in additional animal infection studies."

AVI BioPharma, based in Portland, Ore., develops therapeutic products for the treatment of life-threatening diseases using third-generation Neugene antisense drugs.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.